195 related articles for article (PubMed ID: 38725273)
1. Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions.
Ntobe-Bunkete B; Lemaitre F
Expert Rev Clin Pharmacol; 2024; 17(5-6):505-514. PubMed ID: 38725273
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
Monchaud C; Marquet P
Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
[TBL] [Abstract][Full Text] [Related]
5. Point-of-Care Therapeutic Drug Monitoring for Precision Dosing of Immunosuppressive Drugs.
Taddeo A; Prim D; Bojescu ED; Segura JM; Pfeifer ME
J Appl Lab Med; 2020 Jul; 5(4):738-761. PubMed ID: 32533157
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update.
Kiang TK; Ensom MH
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):545-53. PubMed ID: 27021063
[TBL] [Abstract][Full Text] [Related]
7. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
de Jonge H; Naesens M; Kuypers DR
Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion.
Ehren R; Schijvens AM; Hackl A; Schreuder MF; Weber LT
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):201-213. PubMed ID: 33107768
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic principles of immunosuppressive drugs.
Budde K; Glander P
Ann Transplant; 2008; 13(3):5-10. PubMed ID: 18806727
[TBL] [Abstract][Full Text] [Related]
10. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.
Kuypers DR; Le Meur Y; Cantarovich M; Tredger MJ; Tett SE; Cattaneo D; Tönshoff B; Holt DW; Chapman J; Gelder Tv;
Clin J Am Soc Nephrol; 2010 Feb; 5(2):341-58. PubMed ID: 20056756
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
Staatz CE; Tett SE
Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.
del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ
Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332
[TBL] [Abstract][Full Text] [Related]
13. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients.
Job KM; Roberts JK; Enioutina EY; Illamola SM; Kumar SS; Rashid J; Ward RM; Fukuda T; Sherbotie J; Sherwin CM
Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):747-765. PubMed ID: 34121566
[No Abstract] [Full Text] [Related]
14. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?
Mourad M; Wallemacq P; König J; de Frahan EH; Eddour DC; De Meyer M; Malaise J; Squifflet JP
Clin Pharmacokinet; 2002; 41(5):319-27. PubMed ID: 12036390
[TBL] [Abstract][Full Text] [Related]
15. Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?
Capron A; Haufroid V; Wallemacq P
Pharmacol Res; 2016 Sep; 111():610-618. PubMed ID: 27468645
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
[TBL] [Abstract][Full Text] [Related]
17. Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation.
van Gelder T; Fischer L; Shihab F; Shipkova M
Transplant Rev (Orlando); 2017 Jul; 31(3):151-157. PubMed ID: 28279567
[TBL] [Abstract][Full Text] [Related]
18. [Monitoring and secondary effects of immunosuppressants in the transplant].
Sádaba B
An Sist Sanit Navar; 2006; 29 Suppl 2():207-18. PubMed ID: 16998527
[TBL] [Abstract][Full Text] [Related]
19. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus and everolimus in kidney transplantation.
Moes DJ; Guchelaar HJ; de Fijter JW
Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
